v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
3 Months Ended 9 Months Ended 21 Months Ended
May 03, 2026
Apr. 27, 2025
May 03, 2026
Apr. 27, 2025
May 03, 2026
Cash flows from operating activities:          
Net earnings $ 124 $ 66 $ 463 $ 457  
Adjustments to reconcile net earnings to operating cash flow          
Impairment charges [1] 0 150 0 176  
Restructuring charges [2] 9 6 15 17  
Stock-based compensation     48 52  
Pension and postretirement benefit expense     4 2  
Depreciation and amortization 105 109 306 328  
Deferred income taxes     81 (58)  
Loss on sales of businesses [3] 0 0 0 25  
Other     93 92  
Changes in working capital, net of divestitures          
Accounts receivable     21 (57)  
Inventories     (27) 49  
Other current assets     (52) (17)  
Accounts payable and accrued liabilities     (71) (150)  
Other     (42) (44)  
Net cash provided by operating activities     839 872  
Cash flows from investing activities:          
Purchases of plant assets     (297) (296)  
Purchases of routes     (56) (130)  
Sales of routes     51 96  
Sales of businesses, net of cash divested     5 258  
Other     (1) (8)  
Net cash used in investing activities     (298) (80)  
Cash flows from financing activities:          
Short-term borrowings, including commercial paper     1,376 1,189  
Short-term repayments, including commercial paper     (1,399) (1,093)  
Long-term borrowings     549 1,144  
Long-term repayments     (400) (1,550)  
Dividends paid     (354) (343)  
Treasury stock purchases     (26) (60)  
Payments related to tax withholding for stock-based compensation     (13) (30)  
Payments of debt issuance costs     (5) (12)  
Net cash used in financing activities     (272) (755)  
Effect of exchange rate changes on cash     1 (2)  
Net change in cash and cash equivalents     270 35  
Cash and cash equivalents - beginning of period     132 108 $ 108
Cash and cash equivalents - end of period $ 402 $ 143 $ 402 $ 143 $ 402
[1] In the third quarter of 2025, we recognized an impairment charge of $150 million on our Snyder's of Hanover trademark. In the second quarter of 2025, we recognized an impairment charge of $15 million on our Allied brands trademarks and an impairment charge of $11 million on our Late July trademark.
[2] See Note 8 for additional information.
[3] See Note 4 for additional information.